Jupiter Medical Center Adjusts Visitor Policy, Elective Procedures

Jupiter Medical Center today announced an update to its visitor policy to allow only one healthy visitor at a time, per patient.

Jupiter Medical Center advises visitors will be screened for potential exposure, travel history and upper respiratory tract symptoms. This new policy went into effect on Wednesday, March 18, and will remain in place until further notice.

Jupiter Medical Center is also in the process of rescheduling non-urgent, elective surgeries. This measure will minimize any potential spread among patients, as well as reduce the risk of exposure to team members and frontline providers. Jupiter Medical Center will continue to perform non-elective, urgent and emergency surgeries.

“In accordance with the Centers for Disease Control (CDC) and the American College of Surgeons recommendations, we are rescheduling elective surgeries to protect the health of our patients and caregivers at this time,” said Dr. Amit Rastogi, president and CEO of Jupiter Medical Center. “We recognize the impact on those patients whose procedures are being delayed and certainly look forward to amending our policy as events warrant.”

Jupiter Medical Center continues to conduct multidisciplinary training drills in preparation for screening, diagnosing, isolating and treating any potential cases of COVID-19, as well as ensuring the proper use of personal protective equipment in accordance with the Centers for Disease Control and Prevention recommended guidelines.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version